(Q36600255)

15 August 2017

1 reference

title

RANK ligand inhibition with denosumab for the management of osteoporosis (English)

1 reference

15 August 2017

0 references

E Michael Lewiecki

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

1041-1050

1 reference

How many women have osteoporosis now?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Perspective. How many women have osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The crippling consequences of fractures and their impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The role of the immune system in the pathophysiology of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoclast precursors, RANKL/RANK, and immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

The long and the short of bone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.10.1041

10.1517/14712598.6.10.1041

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference